

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 19-10-2006

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 01-7-2006 TO BE PUBLISHED ON 20-10-2006 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

705/2006	<u>26-6-2006</u> Wyeth, USA (Priority 28-6-05 USA)	“ Compositions and methods for treatment of cycle-related symptoms”
706/2006	Wyeth, USA (Priority 29-6-05 USA)	“Formulations of conjugated estrogens and bazedoxifene”
707/2006	Bristol-Myers Squibb Co, USA (Priority 27-6-05 USA)	“ N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions”
708/2006	Janssen Pharmaceutica N.V., Belgium (Priority 28-6-05 Europe)	“ Quinoline derivatives as antibacterial agents”
709/2006	Sumitomo Chemical Co, Limited, Japan Divisional	“ Plant growth regulators comprising phenyl uracil compound”
710/2006	Sanofi-Aventis Deutschland GmbH, Germany (Priority 28-6-05 Europe)	“ Isoquinoline derivatives”
711/2006	Refractory Intellectual Property GmbH & Co, KG, Austria (Priority 11-7-05 Germany)	“ Tub-like retainer for a nuclear core melt”
712/2006	<u>27-6-2006</u> Pfizer Inc, France (Priority 29-6-05 USA)	“ Prostaglandin derivatives”
713/2006	Otsuka Pharmaceutical Co, Ltd,	“ Orally disintegrating powder

	Japan, (Priority 29-6-05 Japan)	comprising cilostazol ”
714/2006	Pinter S.A, Spain, (Priority 5-8-05 Spain)	“ Guide device for lapping yarns”
715/2006	Sanofi - Aventis, France, (priority 27-6-05 France)	“ 4, 5- diarylpyrrole derivatives, preparation thereof and therapeutic use thereof”
716/2006	Pinter S.A, Spain, (Priority 3-8-05 Spain)	“ Tensioner for condensing bags ”
717/2006	Exelixis Inc, USA, (Priority 27-7-05 USA)	“ Imidazole Based lxr modulators”
718/2006	Exelixis Inc, USA, (Priority 27-7-05 USA)	“ Pyrazole based Lxr modulators ”
719/2006	Sasol Technology (Proprietary) Limited, South Africa, (Priority 27-6-05 South Africa)	“ Particulate fuel”
720/2006	Janssen Pharmaceutica N.V, Belgium, (Priority 28-6-05 Europe)	“ Quinoline derivatives as antibacterial agents”
721/2006	<u>28-06-2006</u> Stiefel Laboratories, Inc, USA (Priority 29-6-05 USA)	“ Topical skin treating compositions”
722/2006	Boehringer Ingelheim International GmbH, Germany, (Priority 30-6-05 Europe)	“ New substituted glycinamides, process for their manufacture and use thereof as medicaments”
723/2006	Sanofi – Aventis	“ Anilines substituted by pyrido

	France, (Priority 08-7-05 France)	[2,3-d]pyrimidines, their preparation, their application in therapeutics”
724/2006	Sanofi-Aventis France (Priority 01-7-05 France)	“Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof”
725/2006	SmithKline Beecham Corporation USA (Priority 23-5-05 USA)	“ Chemical compounds”
	<u>29-6-2006</u>	
726/2006	FMC corporation, USA (Priority 30-6-05 USA)	“ Improved process for preparing (Disubstitutedpropenyl) phenylalkyl substituted heterocycles”
727/2006	FMC corporation, USA (Priority 30-6-05 USA)	“ Improved process for preparing insecticidal(Disubstitutedpropenyl) phenylalkyl substituted heterocycles”
728/2006	FMC corporation, USA (Priority 30-6-05 USA)	“ Improved process for preparing (Disubstitutedpropenyl) phenylalkyl substituted heterocycles”
729/2006	AstraZeneca AB, Sweden (Priority 09-7-05 GB)	“ Chemical compounds”
730/2006	Boehringer Ingelheim International GmbH, Germany (Priority 01-7-05 Europe)	“ 2,4-diamino-pyrimidine”
731/2006	Magnier Philippe, France, (Priority 29-6-05 France)	“ Electric transformer explosion prevention device”
732/2006	GlaxoSmithKline Consumer Healthcare GmbH & Co KG Germany (Priority 01-7-05 GB)	“ Toothbrush”

733/2006	Wyeth, USA (Priority 30-6-05 USA)	“ Amino-5-(5 membered)heteroarylimidazolone compounds and the use thereof for β secretase modulation”
734/2006	Wyeth, USA (Priority 01-7-05 USA)	“Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same”
735/3006	Siegfried Ltd, Switzerland, (Priority 29-6-05 Switzerland)	“ Process for the preparation of 1-[cyano(4-hydroxyphenyl)methyl]cyclohexanol compounds”
736/2006	Dr. Waqar Mehmood Islamabad, Pakistan.	“ An of line solution for remote monitoring and data acquisition for discrete manufacturing”
	<u>30-7-2006</u>	
737/2006	GlaxoSmithKline Biologicals s.a Belgium (Priority 30-6-05 GB)	“Vaccines”
738/2006	Aventis Pharma S.A., France, (Priority 20-7-05 EP)	“1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them”
	<u>01-7-2006</u>	
739/2006	ENI S.p.A., and Enitecnologie S.p.A., Italy (Priority 08-7-05 Italy)	“ Process for improving the quality as a fuel hydrotreated hydrocarbon blends”
740/2006	1. Nighat Sultana, 2. Kaneez Fatima and 3. Nighat Afza PCSIR Karachi, Pakistan	“ A process for the production of metal cleaner (Liquid Form)
741/2006	Bajaj Auto Limited, India, (Priority 1-7-05 India)	“ Method and system for controlling engine noise”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicated their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

753/2004 Invista Technologies
 S.a.r.L.
 USA

“A composition comprising alloy blends of polyurethane and latex rubber for use in inflatable articles “

(Class: INT.CL.: 7: CO8L, 75/00)

139141

This application relates to barrier articles of polyurethane blends or alloys that limit the permeability of gases there through, particularly as used in inflatable sports articles and more particularly as used in soccer balls.

755/2004 Eli Lilly and Company,
USA

“A crystalline form of {2-[1-(3,
5-Bis-trifluoromethyl-benzyl)-5-pyridin-4-YL-1H-[1,
2, 3]
triazol-4-YL]-pyridin-3-YL}-(2-chlorophenyl)-methan
one”

(Class: A61p, 25/24)

139142

Crystalline form of {2-[1-(3,
5-Bis-trifluoromethyl-benzyl)-5-pyridin-4-YL-1H-[1,
2, 3]
triazol-4-YL]-pyridin-3-YL}-(2-chlorophenyl)-methan
one, its process of preparation and its pharmaceutical
composition.

759/2004 Centocor, Inc.,
Pennsylvania

“Methods for producing human erythropoietin
mimetic hinge core mimetibodies”

(Class: INT.CL.7: A61P, 7/00)

139143

This application relates to polypeptide erythropoietin
mimetic hinge core mimetibodies which stimulate the
production of new erythrocytes to replace who have
lost during aging process.

760/2004 BHP Billiton Innovation Pty Ltd., Australia “Method and apparatus for generating power via a gas turbine and a steam turbine”

(Class: INT.CL.7: H02P, H02K, 7/18)

139144

This application relates to power generation through a gas turbine and steam turbine by using coal.

761//2004 Wyeth, U.S.A. “Process for the preparing a pantoprazole multiparticulate formulation”

(Class: A61K, 9/22)

139145

This application relates to pantoprazole sodium multiparticulates which avoid sticking to nasogastric gastronomy tubes.

764/2004 PPG Industries Ohio, Inc., U.S.A. “A method for coating a ceramic substrate comprising applying at least a portion of the substrate, at least one coloured coating composition and applying to at least a portion of the substrate at least one substantially clear coating composition”

(Class: INT.CL.7: C04B, 41/87)

139146

This invention relates to a method for coating a ceramic substrate comprising applying to at least a portion of the substrate at least one colored coating composition comprising at least one curable organic binder and at least one colorant.

769/2004 Syngenta Participations
AG,
Switzerland

“A novel process for the preparation and purification of a mesotrione sample”

(Class: INT.CL.7: C07C, 49/215. 205/06)

139147

This application relates to an improved process for the preparation of mesotrione having low levels of impurities.

770/2004 Almirall Prodesfarma, S.A.
Spain

“ New pyrimidine-2-amine derivatives and pharmaceutical uses thereof”

(INT.CL.7: C07D, 239/24)

139148

This application relates to pyrimidine-2-amine

derivatives which may be used as a potent and selective antagonists of A2 B adenosine receptor.

1073/2004 Unilever Plc,
England

“Packaging system for detergent bars”

(Class: C11D, 12/06)

139149

Comprising relates to a packaging system for shaped detergent products and comprises of a first PET film having a heat set sealable side and a non heat sealable reverse thereof and a second PET film also having a heat sealable side and a non heat sealable reverse thereof. The non heat sealable sides of first and second PET films are adapted to be laminated together wherein detergent can be packed.

637/2006 Syngenta Participations
AG,
Switzerland

“A novel process for the preparation and purification
of a mesotrione sample”

(Class: INT.CL.7: C07C, 49/215, C07C, 205/06)

139150

A process for reducing the levels of undesirable
impurities in a mesotrione sample is disclosed, said
process comprising the steps of:

- i) forming a mesotrione enolate solution in an
aqueous solvent,
- ii) carrying out one or more purification
processes, and
- iii) crystallizing the purified mesotrione out of
solution.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

138953 Citicorp Credit Services, Inc,
USA

392/2004

138954	Invista Technologies S.a.r.L USA	396/2004
138955	1. Neuralab Limited 2. Wyeth, USA	400/2004
138956	De La Rue International Ltd., U.K.	402/2004
138957	Lite-On Technology corporation, Republic of China	409/2004
138958	Dredging International N.V. Belgium	427/2004
138959	Urea Casale S. A., Switzerland	467/2004
138960	De La Rue International Ltd, U.K.	55/2006

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488